A multinational investigation of the impact of subcutaneous sumatriptan. I: Design, methods and clinical findings

PharmacoEconomics

Volumn 11, Issue SUPPL. 1, 1997, Pages 11-23

  Heywood, J ^a   Bouchard, J ^b   Cortelli, P ^c   Dahlof C ^d   Jansen, J P ^e   Pham, S ^f   Hirsch, J ^g   Edwards, C E ^h   Adams, J ^h   Berto, P ⁱ   Brueggenjuergen, B ^j   Nyth, A L ^f   Lindsay, P ^f   Price, K L ^h  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b Clinical Research Department   (Canada)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d Gothenburg Migraine Clinic   (Sweden)

^e Schmerz Zentrum Berlin GmbH   (Germany)

^f GLAXOSMITHKLINE   (United States)

^g Hirsch Reid Consulting   (United States)

^h GLAXOSMITHKLINE   (United Kingdom)

ⁱ GSK   (Italy)

^j Glaxo Wellcome ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CODEINE; DIAZEPAM; DIMENHYDRINATE; IBUPROFEN; PARACETAMOL; SUMATRIPTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; MULTICENTER STUDY; NAUSEA; PATIENT SATISFACTION; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; SOCIOECONOMICS; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING; WELLBEING; WORKPLACE;

EID: 8544254673     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199700111-00004     Document Type: Article

References (28)

1. De Lissovoy G, Lazaru SS. The economic cost of migraine. Neurology 1994; 44 Suppl. 4: S56-62
2. Greiner DL, Addy SN. Sumatriptan use in a large group-model maintenance organization. Am J Health Syst Pharm 1996; 53: 633-8
3. Stewart WF, Lipton RB. The economic and social impact of migraine. Euro Neurol 1994; 34 Suppl. 2: 12-7
4. Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 1994; 28: 659-64
5. Cull RE, Wells NEJ, Miocevich ML. The economic cost of migraine. Br J Med Econ 1992; 2: 103-15
6. Van Roijen L, Essink-Bot ML, Koopmanschap MA. Societal perspective on the burden of migraine in The Netherlands. PharmacolEconomics 1995; 7 (2): 170-9
7. Clarke CE, MacMillan L, Sondi S, et al. Economic and social impact of migraine. Q J Med 1996; 89: 77-85
8. Prevalence of chronic migraine headaches - United States, 1980-1989. MMWR Morb Mortal Wkly Rep 1991; 40: 331
9. Lipton RB, Stewart WF. Health-related quality of life in headache research. Headache 1995; 35 (8): 447-8
10. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325: 316-21
11. Cady RK, Wendt JK, Kirchner JF, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991; 265: 2831-5
12. Schoen J, Bulcke J, Caekebeke J, et al. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study. Cephalalgia 1994; 14: 55-63
13. The Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol 1991; 31: 323-31
14. Mushet GR, Miller DW, Clements W, et al. Impact of sumatriptan on workplace productivity, non-work activities, and health-related quality of life among hospital employees with migraine. Headache 1996; 36: 137-43
15. Jhingren P, Cady RK, Rubino J, et al. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract 1996; 42 (1): 36-42
16. Dahlöf C, Bouchard J, Cortelli P, et al. A multinational investigation of the impact of subcutaneous sumatriptan. II: health-related quality of life. PharmacoEconomics 1997; 11 Suppl. 1: 24-34
17. Cortelli P, Bouchard J, Dahlöf C, et al. A multinational investigation of the impact of subcutaneous sumatriptan. III: workplace productivity and non-workplace activity. PharmacoEconomics 1997; 11 Suppl. 1: 35-42
18. Bouchard J, Cortelli P, Dahlöf C, et al. A multinational investigation of the impact of subcutaneous sumatriptan. IV: patient satisfaction. PharmacoEconomics 1997; 11 Suppl. 1: 43-50
19. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1-96
20. Ware JE. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, 1993
21. Ware JE, Sherbourne CD. The MOS-36-Item Short-Form Health Survey (SF-36). Med Care 1992; 30: 474-83
22. Miller DW, Kirchdoerfer LJ, Shepherd MD, et al. A disease specific instrument to measure quality of life effects attributable to migraine. Poster presentation at the Health Services Research Association 10th Annual Meeting; Jun 27-29, 1993: Washington DC
23. Cohen JA, Beall DG, Miller DW, et al. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic and clinical consequences. Fam Med 1996; 28: 171-7
24. Boureau F, Chazot G, Emile J, et al. Comparison of subcutaneous sumatriptan with usual acute treatments for migraine. French Sumatriptan Study Group. Eur Neurol 1995; 35 (5): 264-9
25. Blau JN. Adult migraine: the patient observed. In: Blau JN, editor. Migraine: clinical, therapeutic, conceptual and research aspects. London: Chapman & Hall, 1987: 3-30
26. Lance JW, Anthony M. Some clinical aspects of migraine: a prospective survey of 500 patients. Arch Neurol 1966; 15: 356-61
27. Chazot G, Boureau F, Emile J, et al. Comparison of sumatriptan with usual acute treatment of migraine. Cephalalgia 1993; 13 Suppl. 13: 162
28. Miller DW, Osterhaus JT, Hirsch JD, et al. Quality of life assessment among migraineurs treated with sumatriptan: preliminary findings. 35th Annual Scientific Meeting for the American Association for the Study of Headache (AASH). Headache 1993; 33 (5): 278